JointHealth™ insight – été 2017
C’est l’été ! Quoi de neuf sous le soleil dans la recherche sur l’arthrite ?
Dans cette édition d’été du JointHealth™ insight, nous faisons un compte rendu des nouvelles informations présentées dans le cadre du congrès annuel de la Ligue européenne contre le rhumatisme (EULAR), tenu à Madrid, en Espagne, en juin 2017. Parmi ces nouveautés présentées par l’EULAR, mentionnons :
- La campagne de l’EULAR « Don’t Delay, Connect Today » pour améliorer les modèles de soins pour l’arthrite inflammatoire
- Des études sur l’immunogénicité qui démontrent que le traitement au moyen de biosimilaires ou de biologiques d’origine donne des résultats comparables
- Les conclusions d’une recherche au Danemark indiquant qu’aucune augmentation d’utilisation des ressources en santé n’a été constatée après la mise en application de la politique de transition vers les biosimilaires
- Des pratiques exemplaires pour éduquer les patients sur les biosimilaires
Également dans ce numéro :
- De l’information sur un nouvel outil sur l’arthrose à l’intention des médecins de famille
- Profil d’un scientifique en herbe sur les biomarqueurs et l’arthrose, dans un contexte de recherche
Quoi de neuf sous le soleil dans la recherche sur l’arthrite ?
JointHealth™ insight – Summer 2017
It’s summertime: What’s hot in arthritis research?
In this summer issue of JointHealth™ insight, we report on new information presented at the European League Against Rheumatism (EULAR) Annual Congress, which took place in Madrid, Spain, in June 2017. EULAR updates covered include:
- EULAR’s “Don’t Delay, Connect Today” campaign to improve models of care for inflammatory arthritis
- Immunogenicity studies that show comparable results between biosimilars and originator biologics
- Research from Denmark finds no higher patient use of health services after policy transition to biosimilars
- A best practice spotlight on helping patients understand biosimilars
In this issue, you will also find:
- Information about a new Osteoarthritis (OA) Tool for family physicians
- A profile of a young scientist’s research journey looking at osteoarthritis and biomarkers
What’s hot in arthritis research?
At this year’s annual EULAR 2017 annual congress, attendees learned about the need for increased collaboration between adult and paediatric rheumatologists to improve outcomes of adults living with active juvenile idiopathic arthritis (JIA).
According to conclusions from a review of more than 50 studies and approximately 3,000 JIA patients, half of adults living with JIA were not receiving adequate treatment, despite the fact that biological have been shown to improve the quality of life in children with JIA, with most of these benefits of treatment in childhood persisting into adulthood.
Presenting the results of her study, Dr. Berit Flato from the rheumatology department at Oslo University Hospital said: “Since 2000, biological and methotrexate have been prescribed earlier in JIA, resulting in increased rates of inactive disease after 1-3 years. Yet, recent reports indicate that only half of adult patients with JIA are on synthetic or biological disease-modifying anti-rheumatic drug (DMARDs).
The inadequate treatment identified in the study partly explains why adults with JIA often experience more pain, poorer health-related quality of life, and lower employment rates.
ACE Founder and President, Chery Koehn, related the study results to the Canadian environment: “The reasons why many adult patients with JIA in Canada fall through this treatment gaps are many. A large factor is the transition of children with JIA from paediatric care to adult care, which often is not as smooth as it should be.”
JIA affects approximately 24,000 children and teens in Canada, making it one of the most common causes of chronic disability in children. JIA can be devastating and comes with high financial, family and societal burdens. Approximately 60% of children will have active disease into childhood. For more information about JIA, please visit Cassie and Friends, the only charity in Canada dedicated 100# to the paediatric rheumatic disease community (Cassie & Friends).
From this year’s EULAR annual conference comes major news for people living with spondyloarthritis (SpA). Based on recommendations from a task force of European and North American patients, rheumatologists, dermatologists, and health professionals, new treat-to-target (T2T) guidelines for SpA were announced that emphasize the importance to set a target in shared decision making between a specialist and patient and carefully monitor the disease in order to improve a patient’s health outcome.
“The T2T recommendations are following the principle that you have to define a target you want to reach and adapt management to reach this target. This is independent of the treatment you use to reach the target,” said Professor Desiree van der Hejde, a professor at Leiden University Medical Centre in the Netherlands. Continue reading